Commercial Credit Report for CTI BioPharma Corp

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for CTI BioPharma Corp is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

CTI BioPharma Corp

3101 Western Avenue, Suite 800

Phone: (206) 282-7100p:206 282-7100

SEATTLE, WA 98121 United States

Fax: (206) 284-6206f:206 284-6206

This company was Merged or Acquired on 6/26/2023.

This company ceased filing statements with the SEC on 7/6/2023.

This company is no longer actively traded on any major stock exchange.

This is a Subsidiary, click here for the Parent Company

Business Summary

CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	Morningstar DBRS Rating
-	Yes	-	Yes	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
3/31/2023	12/31/2022	Yes	Yes	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
2833	Medicinal chemicals and botanical products

Officers and Directors

Title	Name	Age	Title Date	Start Date
Non-Executive Independent Chairman of the Board	LaurentFischer	59	9/26/2017	7/21/2017
President, Chief Executive Officer, Interim Chief Medical Officer, Director	Adam R.Craig	57	3/20/2017	3/20/2017
Chief Financial Officer, Executive Vice President, Secretary	David H.Kirske	68	9/1/2017	9/1/2017
5 additional Officers and Directors records available in full report.

Business Names

Business Name
Aequus Biopharma, Inc.
CEPS
Novuspharma SpA

General Information

Number of Employees:	128	(As of 12/31/2022)
Outstanding Shares:	131,880,176	(As of 5/4/2023)
Shareholders:	106
Stock Exchange:	NASD
Federal Tax Id:	911533912
Fax Number:	(206) 284-6206
Email Address:	invest@ctiseattle.com

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN